Network Meta-Analysis of Time-to-Event Endpoints With Individual Participant Data Using Restricted Mean Survival Time Regression

被引:0
|
作者
Hua, Kaiyuan [1 ]
Wang, Xiaofei [1 ]
Hong, Hwanhee [1 ]
机构
[1] Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham,NC, United States
关键词
D O I
10.1002/bimj.70037
中图分类号
学科分类号
摘要
Network meta-analysis (NMA) extends pairwise meta-analysis to compare multiple treatments simultaneously by combining direct and indirect comparisons of treatments. The availability of individual participant data (IPD) makes it possible to evaluate treatment effect moderation and to draw inferences about treatment effects by taking the full utilization of individual covariates from multiple clinical trials. In IPD-NMA, restricted mean survival time (RMST) models have gained popularity when analyzing time-to-event outcomes because RMST models offer more straightforward interpretations of treatment effects with fewer assumptions than hazard ratios commonly estimated from Cox models. Existing approaches estimate RMST within each study and then combine by using aggregate-level NMA methods. However, these methods cannot incorporate individual covariates to evaluate the effect moderation. In this paper, we propose advanced RMST NMA models when IPD are available. Our models allow us to study treatment effect moderation and provide a comprehensive understanding about comparative effectiveness of treatments and subgroup effects. The methods are evaluated by an extensive simulation study and illustrated using a real NMA example about treatments for patients with atrial fibrillation. © 2025 Wiley-VCH GmbH.
引用
下载
收藏
相关论文
共 50 条
  • [1] Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data
    Wei, Yinghui
    Royston, Patrick
    Tierney, Jayne F.
    Parmar, Mahesh K. B.
    STATISTICS IN MEDICINE, 2015, 34 (21) : 2881 - 2898
  • [2] Using Restricted Mean Survival Time to Improve Interpretability of Time-to-Event Data Analysis
    Charu, Vivek
    Tian, Lu
    Tamura, Manjula Kurella
    Montez-Rath, Maria E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (02): : 260 - 262
  • [3] Using median survival in meta-analysis of experimental time-to-event data
    Hirst, Theodore C.
    Sena, Emily S.
    Macleod, Malcolm R.
    SYSTEMATIC REVIEWS, 2021, 10 (01)
  • [4] Using median survival in meta-analysis of experimental time-to-event data
    Theodore C. Hirst
    Emily S. Sena
    Malcolm R. Macleod
    Systematic Reviews, 10
  • [5] Novel methodology in network meta-analysis of time-to-event data using blended survival curves
    Che, Zhaojing
    Green, Nathan
    Baio, Gianluca
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP98 - NP99
  • [6] Penalized Poisson model for network meta-analysis of individual patient time-to-event data
    Ollier, Edouard
    Blanchard, Pierre
    Le Teuff, Gwenael
    Michiels, Stefan
    STATISTICS IN MEDICINE, 2022, 41 (02) : 340 - 355
  • [7] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723
  • [8] Individual participant data meta-analysis of intervention studies with time-to-event outcomes: A review of the methodology and an applied example
    de Jong, Valentijn M. T.
    Moons, Karel G. M.
    Riley, Richard D.
    Tudur Smith, Catrin
    Marson, Anthony G.
    Eijkemans, Marinus J. C.
    Debray, Thomas P. A.
    RESEARCH SYNTHESIS METHODS, 2020, 11 (02) : 148 - 168
  • [9] DISCRETE TIME RESTRICTED CUBIC SPLINE MODELS FOR NETWORK META-ANALYSIS OF TIME-TO-EVENT OUTCOMES
    Pletscher, M.
    Gsteiger, S.
    VALUE IN HEALTH, 2019, 22 : S520 - S520
  • [10] Restricted mean survival time as a summary measure of time-to-event outcome
    Hasegawa, Takahiro
    Misawa, Saori
    Nakagawa, Shintaro
    Tanaka, Shinichi
    Tanase, Takanori
    Ugai, Hiroyuki
    Wakana, Akira
    Yodo, Yasuhide
    Tsuchiya, Satoru
    Suganami, Hideki
    PHARMACEUTICAL STATISTICS, 2020, 19 (04) : 436 - 453